Osteologix Holdings (OLGXF) 0.0060 $OLGXF Post

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Osteologix Holdings (OLGXF) 0.0060 $OLGXF

Post Menopausal Osteoporosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kgcd25/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Merck & Co - Pfizer - Osteologix Holdings - Unigene Laboratories - Radius Health - Chronos Therapeutics - Amgen Astellas BioPharma - Paras Biopharmaceuticals Finland For more information visit http://www.researchandmarkets.com/research/kg...menopausal
RDUS: 43.18 (-1.10), MRK: 57.25 (-0.18), AMGN: 163.38 (+1.89)

Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 163.38 (+1.89), LLY: 73.92 (+1.56)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stocks Jump Ahead of Critical Inflation Reports

Updated Category News Views 129

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

Continue Reading
AutoMobility LA: Autonomous Tech's Big Leap

Updated Category News Views 61

Rolling Toward an Autonomous Future Alright, gearheads and tech buffs alike, gather 'round for a ride into the future of road travel. AutoMobility LA, a brainchild of the Los Angeles Auto Show, is revving up to give us a sneak peek into the era where cars don't just roll—they think. "The future's not about who's behind the wheel, but who's crafting the brain of the...

Continue Reading
Hyperscale Data Plans Major Stock Exchange Deal

Updated Category News Views 80

Hyperscale's Bold Move: Exchange Offer Hits the Market Man, when a company believes its market value is out of whack, you get moves like this. Hyperscale Data, strutting under ticker symbol NYSE:GPUS, is swinging for the fences with an exchange offer, aiming to mop up $50 million worth of its common stock with a sweet deal that’s sure to grab any investor's attention....

Continue Reading
Cloud Software Group's $2B Debt Offer Wraps Up

Updated Category News Views 101

Sizing Up Cloud Software Group’s Recent Maneuver Whoever thought navigating debt was a dull spectacle hasn’t kept up with Cloud Software Group's recent financial theatrics. With a $2 billion cap on the table, their cash tender offer for 9.00% Senior Secured Second Lien Notes due 2029 didn’t just happen; it paraded onto the financial stage and left a noteworthy...

Continue Reading
Chipotle's BOGO Promo Returns: Tattoos Boost Sales

Updated Category News Views 101

Chipotle's BOGO Charade: A Tattooed Affair You've got to hand it to Chipotle—they know how to turn heads and wallets with their quirky promotions. The upcoming 'Tatted Like a Chipotle Bag' offer is a prime example of how they ride the cultural zeitgeist as they gear up for another record-breaking day on Friday, November 13. And seriously, with tattoos in play, they're...

Continue Reading
Energenesis Tackles Space Anemia with ATP Boost

Updated Category News Views 84

Gearing Up for Space Medicine: Enter Energenesis With the cosmic frontier drawing investor eyes and day-to-day operations inching skyward, here comes Energenesis Biomedical (TWSE: 6657), poking its head into space medicine. This isn’t just another biotech firm looking to throw drugs at terrestrial problems. No, Energenesis shot its shot at TASTI 2026 with its...

Continue Reading
Guizhou's Mountain Conference Pushes Tourism Evolution

Updated Category News Views 28

Climbing High: Guizhou's Tourism Summit The 2026 International Conference of Mountain Tourism and Outdoor Sports in Guizhou has kicked off with a heartfelt focus on merging natural allure with modern tourism. This isn't just another gathering; it's a powerhouse of international dialogue harbored right in China's dramatic landscape. Building on Unique Natural Assets...

Continue Reading
Bybit Shines at Web Summit 2026 as AI Takes Center Stage

Updated Category News Views 95

Financial Revolution: Bybit Steals the Spotlight Ever been to a tech show where financial bigwigs mingle with code geeks? Well, that's exactly the scene unfolding at the famed Web Summit 2026, with Bybit throwing down the gauntlet as an official partner. The MEO Arena in Lisbon is buzzing more than a stock ticker on a rollercoaster day, as Bybit flaunts its wares to a...

Continue Reading
Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Updated Category News Views 97

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Continue Reading
NSAP's First Board Aims to Revolutionize Autism Care

Updated Category News Views 61

Out in Silicon Valley, where innovation isn’t just a buzzword, the National Society of Autism Professionals (NSAP) is stirring the pot with some serious leadership moves. Just this month, they cobbled together their inaugural board of directors—a gathering of eight experts from every corner of the autism field you can think of. They’re not playing small ball, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Seafood Summit 2026: Deepening Industry Insights

Updated Category News Views 30

Gearing Up for the 2026 Responsible Seafood Summit In these jittery market waters and unpredictable times, the seafood industry is gathering its heavyweights in Bangkok this September. The Global Seafood Alliance (GSA), along with The Center for Responsible Seafood, is rolling out the red carpet for the 25th Responsible Seafood Summit at the plush Shangri-La Bangkok. Mark...

Continue Reading
Investigation into DeFi Technologies: What Investors Should Know

Updated Category News Views 106

Understanding the Investigation into DeFi Technologies Faruqi & Faruqi, LLP, a reputable name in securities litigation, is currently looking into claims on behalf of investors associated with DeFi Technologies, Inc. This emerging tech company, identified on the NASDAQ under the ticker DEFT, has become the subject of scrutiny as they deal with various shareholder concerns....

Continue Reading
Mid-Cap Stock Highlights: Akero, Brinker, and Viavi Surge

Updated Category News Views 109

Top Performing Mid-Cap Stocks The mid-cap sector has witnessed remarkable movements lately, with several stocks showing impressive gains. Investors are keen to track these stocks, as their performance can significantly influence portfolios. Below we explore the notable performers. Akero Therapeutics Leads the Pack Akero Therapeutics, Inc. (NASDAQ: AKRO) recently made...

Continue Reading
Sigma Defense Joins NSA's Trusted Integrator Roster

Updated Category News Views 15

A Big League Certification You know, when a defense company like Sigma Defense Systems lands the Trusted Integrator badge from the NSA, it’s no small potatoes. This isn’t just some badge of merit; it’s essentially an entry to the big leagues in terms of secure tech integration. We’re talking about handling the crown jewels of national security data with commercial...

Continue Reading
Clorox Delivers Strong Q1 Results Amid Cyber Challenges

Updated Category News Views 89

Clorox Demonstrates Strong Performance in Q1 Recently, Clorox (NYSE: CLX) has showcased impressive financial results for the first quarter, leading Jefferies to maintain a Buy rating on the stock while slightly raising the price target to $188 from $187. This upward adjustment illustrates the firm's confidence in Clorox's effective management and resilience following the...

Continue Reading